GSK PLC-SPON ADR (GSK) Stock Price, Quote, News and Overview
NYSE:GSK - New York Stock Exchange, Inc. - US37733W2044 - ADR - Currency: USD
GSK Quote, Performance and Key Statistics
38.54
+0.14 (+0.36%)
The current stock price of GSK is 38.54 USD. In the past month the price increased by 4.08%. In the past year, price decreased by -14.58%.
GSK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52.69 | 687.25B | ||
| JNJ | JOHNSON & JOHNSON | 15.24 | 368.56B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.6 | 302.74B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.57 | 222.75B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.73 | 216.03B | ||
| MRK | MERCK & CO. INC. | 9.88 | 193.71B | ||
| PFE | PFIZER INC | 7.18 | 130.67B | ||
| SNY | SANOFI-ADR | 13.88 | 129.50B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.4 | 95.65B | ||
| ZTS | ZOETIS INC | 26.82 | 72.01B | ||
| HLN | HALEON PLC-ADR | 22.65 | 50.05B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 26.52 | 45.07B |
Related stock screener links
About GSK
Company Profile
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 68,629 full-time employees. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes the lead molecule IDRX-42, highly selective tyrosine kinase inhibitor (TKI) that is designed to improve patients with gastrointestinal stromal tumors (GIST).
Company Info
GSK PLC-SPON ADR
980 Great West Road
Brentford MIDDLESEX TW8 9GS GB
CEO: Emma Walmsley
Employees: 68629
Phone: 442080475000
GSK PLC-SPON ADR / GSK FAQ
What is the stock price of GSK PLC-SPON ADR today?
The current stock price of GSK is 38.54 USD. The price increased by 0.36% in the last trading session.
What is the ticker symbol for GSK PLC-SPON ADR stock?
The exchange symbol of GSK PLC-SPON ADR is GSK and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is GSK stock listed?
GSK stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for GSK PLC-SPON ADR stock?
31 analysts have analysed GSK and the average price target is 44.98 USD. This implies a price increase of 16.71% is expected in the next year compared to the current price of 38.54. Check the GSK PLC-SPON ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GSK PLC-SPON ADR worth?
GSK PLC-SPON ADR (GSK) has a market capitalization of 77.98B USD. This makes GSK a Large Cap stock.
How many employees does GSK PLC-SPON ADR have?
GSK PLC-SPON ADR (GSK) currently has 68629 employees.
What are the support and resistance levels for GSK PLC-SPON ADR (GSK) stock?
GSK PLC-SPON ADR (GSK) has a support level at 38.48 and a resistance level at 39.08. Check the full technical report for a detailed analysis of GSK support and resistance levels.
Is GSK PLC-SPON ADR (GSK) expected to grow?
The Revenue of GSK PLC-SPON ADR (GSK) is expected to grow by 4.28% in the next year. Check the estimates tab for more information on the GSK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GSK PLC-SPON ADR (GSK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GSK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GSK, evaluating the profitability, health, valuation and growth aspects
- GSK PLC-SPON ADR (GSK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GSK PLC-SPON ADR (GSK) Sales and EPS estimates to see what analysts future expectations are.
- GSK PLC-SPON ADR (GSK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GSK PLC-SPON ADR (GSK) Insider and Institutional Ownership to learn about the owners and their transactions.
- GSK PLC-SPON ADR (GSK) Stock Chart to make your own analysis
- GSK PLC-SPON ADR (GSK) Latest news and press-releases to stay up to date.
Does GSK PLC-SPON ADR (GSK) stock pay dividends?
GSK PLC-SPON ADR (GSK) has a dividend yield of 4.55%. The yearly dividend amount is currently 1.62. Check the full fundamental report for a detailed analysis of GSK dividend history, reliability and sustainability.
When does GSK PLC-SPON ADR (GSK) report earnings?
GSK PLC-SPON ADR (GSK) will report earnings on 2025-07-30, before the market open.
What is the Price/Earnings (PE) ratio of GSK PLC-SPON ADR (GSK)?
The PE ratio for GSK PLC-SPON ADR (GSK) is 7.03. This is based on the reported non-GAAP earnings per share of 5.48 and the current share price of 38.54 USD. Check the full fundamental report for a full analysis of the valuation metrics for GSK.
What is the Short Interest ratio of GSK PLC-SPON ADR (GSK) stock?
The outstanding short interest for GSK PLC-SPON ADR (GSK) is 0.87% of its float. Check the ownership tab for more information on the GSK short interest.
GSK Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GSK. When comparing the yearly performance of all stocks, GSK is a bad performer in the overall market: 61.8% of all stocks are doing better.
GSK Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GSK. While GSK belongs to the best of the industry regarding profitability, there are concerns on its financial health.
GSK Financial Highlights
Over the last trailing twelve months GSK reported a non-GAAP Earnings per Share(EPS) of 5.48. The EPS increased by 24.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10% | ||
| ROA | 5.19% | ||
| ROE | 22.27% | ||
| Debt/Equity | 1.16 |
GSK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 56% to GSK. The Buy consensus is the average rating of analysts ratings from 31 analysts.
For the next year, analysts expect an EPS growth of 8.58% and a revenue growth 4.28% for GSK